Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Recruiting

• Conditions: Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type

• Registration Number: NCT05046080
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.

Detailed Description

PRIMARY OBJECTIVE:

I. To perform a retrospective clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix at M D Anderson Cancer Center (MDACC) and to delineate the immunohistochemical and molecular profile of these cases.

OUTLINE:

Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.

Study Timeline

• Study Start: 2021-08-06
• Study First Submitted: 2021-08-25
• Study First Submitted QC: 2021-09-13
• Study First Posted: 2021-09-16
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-13
• Last Update Posted: 2025-08-15
• Primary Completion: 2026-09-29
• Study Completion: 2026-09-29

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 70

Inclusion Criteria

• Patients diagnosed with clear cell carcinoma of the cervix at MDACC

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix	through study completion, an average of 1 year

Trial Locations

Locations (1)

M D Anderson Cancer Center; 🇺🇸 Houston, Texas, United States